Abstract
The purpose of this study is to provide the researchers with the bigger academic network for the understanding of the incorporated proof about current pharmacogenomics information on pediatric oncology and hematology. This primary assessment will help and guide the researchers and clinicians by giving a thought about the current situation of research, as far as customizing drug for kids with malignant growth (cancer). This study also describes the gene-drug associations with substantial and adequate power of association put forward by PharmGKB (Pharmacogenomics Knowledgebase). Some drugs with strong pharmacogenetic evidence like thiopurines and some with moderate pharmacogenetic evidence like vincristine are also discussed. Upcoming suggestions to achieve this objective will help to put forward the recommendations. Pharmacogenetic gene-drug link studies, thus, influence the reconsidering of study plans to produce sensible results. Genetic roots of oxidative force reaction or genome stability disturbing reaction were categorized as association with moderate evidence but have not yet been tested in children.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101–121
Pritchard-Jones K, Dixon-Woods M, Naafs-Wilstra M, Valsecchi MG (2008) Improving recruitment to clinical trials for cancer in childhood. Lancet Oncol 9(4):392–399
Mitchell AA, Lacouture PG, Sheehan JE, Kauffman RE, Shapiro S (1988) Adverse drug reactions in children leading to hospital admission. Pediatrics 82(1):24–29
MacNeil M, Eisenhauer E (1999) High-dose chemotherapy: is it standard management for any common solid tumor? Ann Oncol 10(10):1145–1161
Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56(4):247–258
Stevens A, Hanson D, Whatmore A, Destenaves B, Chatelain P, Clayton P (2013) Human growth is associated with distinct patterns of gene expression in evolutionarily conserved networks. BMC Genomics 14(1):547
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714
Longley D, Johnston P (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275–292
Bar-Shalom D, Rose K (2014) Pediatric formulations: a roadmap, vol 11. Springer, New York
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167
Leeder JS, Kearns GL (1997) Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin N Am 44(1):55–77
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A. Clin Pharmacokinet 37(6):485–505
Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN, Pediatric Transporter Working Group (2015) Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther 98(3):266–287
Finkielstain GP, Forcinito P, Lui JC, Barnes KM, Marino R, Makaroun S, Nguyen V, Lazarus JE, Nilsson O, Baron J (2008) An extensive genetic program occurring during postnatal growth in multiple tissues. Endocrinology 150(4):1791–1800
Knight KRG, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23(34):8588–8596
Kushner BH, Budnick A, Kramer K, Modak S, Cheung NKV (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107(2):417–422
Bleyer W, Fallavollita J, Robison L, Balsom W, Meadows A, Heyn R, Sitarz A, Ortega J, Miller D, Constine L (1990) Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children’s Cancer Study Group. Pediatr Hematol Oncol 7(4):329–338
Lazaryan M, Shasha-Zigelman C, Dagan Z, Berkovitch M (2015) Codeine should not be prescribed for breastfeeding mothers or children under the age of 12. Acta Paediatr 104(6):550–556
Uppugunduri RS, Ansari M (2016) Commentary: a myriad aberrations on information of ontogeny of drug metabolizing enzymes in the pediatric population: an obstacle for personalizing drug therapy in the pediatric population. Drug Metab Lett 10(2):72–74
Whirl-Carrillo M, McDonagh EM, Hebert J, Gong L, Sangkuhl K, Thorn C, Altman RB, Klein TE (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92(4):414–417
Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, Weinshilboum R (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15(1):17–30
Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651
Collie-Duguid E, Pritchard S, Powrie R, Sludden J, Collier D, Li T, McLeod H (1999) The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9(1):37–42
Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, Marinaki T, McLeod HL, Relling MV, Schaeffeler E, Schwab M, Weinshilboum R, Yeoh AE, McDonagh EM, Hebert JM, Klein TE, Coulthard SA (2013) Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 23(4):242
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91(23):2001–2008
Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri C, Krajinovic M, Ansari M (2016) Pharmacogenomics in pediatric oncology: review of gene—drug associations for clinical use. Int J Mol Sci 17(9):1502
Relling M, Gardner E, Sandborn W, Schmiegelow K, Pui CH, Yee S, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium (2011) Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89(3):387–391
Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A-H, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 89(5):662–673
Pui C-H, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2):166–178
Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci 90(20):9552–9556
Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361–367
Xie H-G, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3):243–272
Moore AS, Norris R, Price G, Nguyen T, Ni M, George R, van Breda K, Duley J, Charles B, Pinkerton R (2011) Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 47(12):875–882
Sims RP (2016) The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract 22(1):76–81
Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Wheeler HE (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313(8):815–823
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Zafar, B., Ghaffar, M., Salahuddin, H. (2020). History of Drug Reaction in Children Suffering from Cancer. In: Masood, N., Shakil Malik, S. (eds) 'Essentials of Cancer Genomic, Computational Approaches and Precision Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-15-1067-0_15
Download citation
DOI: https://doi.org/10.1007/978-981-15-1067-0_15
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-1066-3
Online ISBN: 978-981-15-1067-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)